Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Expenses (2024 - 2025)

Indivior Pharmaceuticals has reported Operating Expenses over the past 2 years, most recently at $211.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $211.0 million for Q4 2025, up 2.93% from a year ago — trailing twelve months through Dec 2025 was $732.0 million (down 20.43% YoY), and the annual figure for FY2025 was $732.0 million, down 20.35%.
  • Operating Expenses for Q4 2025 was $211.0 million at Indivior Pharmaceuticals, up from $187.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for INDV hit a ceiling of $338.0 million in Q2 2024 and a floor of $156.0 million in Q1 2025.